Characteristics of patients who received antifibrotic treatment and those who did not
| Patients with >6 months treatment | Patients without treatment or <6 months treatment | Difference between groups p-value | |
| Patients | 95 | 358 | |
| Age at diagnosis years | 67.4±7.8 | 74.5±8.8 | <0.0001 |
| Sex | 0.003 | ||
| Male | 74 (77.9%) | 221 (61.7%) | |
| Female | 21 (22.1%) | 137 (38.3%) | |
| BMI kg·m−2 | 29.0±5.3 | 28.2±5.1 | 0.207 |
| Smoking | 0.015 | ||
| Never smoker | 31 (33.3%) | 166 (48.1%) | |
| Ex-smoker | 57 (61.3%) | 153 (44.4%) | |
| Current smoker | 5 (5.4%) | 26 (7.5%) | |
| DLCO % predicted | 53.2±14.1 | 56.5±16.9 | 0.111 |
| FVC L | 2.8±0.7 | 2.7±0.9 | 0.338 |
| FVC % predicted | 72.4±13.6 | 82.4±18.7 | <0.0001 |
| GAP stage | 0.006 | ||
| GAP 1 | 33 (40.2%) | 167 (58.0%) | |
| GAP 2 | 46 (56.1%) | 105 (36.5%) | |
| GAP 3 | 3 (3.7%) | 16 (5.6%) | |
| Transplantation | 7 (7.3%) | 6 (1.7%) | |
| Deaths | 25 (26.3%) | 154 (43.0%) | |
| IPF-related deaths | 21 (84.0%) | 93 (60.8%) |
Data are presented as mean±sd unless otherwise stated. BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis. Bold indicates statistically significant p-values.